Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class ...

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo Company, in collaboration ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...

Dato-DXd improved outcomes over chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who were ineligible for immunotherapy.

Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...

Discover how the neoadjuvant T-DXd-THP regimen significantly improves complete response rates and safety over standard ...

DXd-THP achieved a pCR rate of 67.3% versus 56.3% with ddAC-THP, "the highest reported pCR rate in HER2-positive early breast ...

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...